PlainPharmaWatch

CMS Open Payments · Program Year 2024

Taiho Oncology, Inc.

Taiho Oncology, Inc. reported $17,611,301.25 in payments to 5,970 physicians and teaching hospitals across 6,767 transactions.

See the rankings → How this is sourced
$17.6M
Total payments
6,767
Transactions
5,970
Recipients
−$811.9K
General Payments vs PY2023

Taiho Oncology, Inc. reported $17,611,301.25 in payments to 5,970 physicians and teaching hospitals in CMS Open Payments Program Year 2024 - ranking #104 of 1,925 reporting manufacturers (0.1% of all US industry payments), averaging $2.9K per recipient across 7 payment categories. Figures are company-reported under the Physician Payments Sunshine Act; a reported payment is a financial relationship, not evidence of wrongdoing.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the editorial team.

The verdict

Taiho Oncology, Inc. pairs top-10% payment volume with an unusually diversified payment pattern across a wide recipient base.

#104
of 1,925 companies
0.1%
of all US industry payments
0.1%
paid to its single top recipient
7
payment categories

Release-over-release change

General Payments changed from PY2023 to PY2024

Taiho Oncology, Inc.'s CMS-reported General Payments decreased by $811.9K (−49.0%) from PY2023 to PY2024. The comparison uses the same CMS manufacturer-by-payment-category summary for both years and excludes research and ownership or investment records.

CMS source labels for this exact identifier: PY2022: TAIHO ONCOLOGY, INC.PY2023: TAIHO ONCOLOGY, INC.PY2024: TAIHO ONCOLOGY, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.7MPY2024$844.4K
PY2023
$1,656,279.19
PY2024
$844,416.49

How Taiho Oncology, Inc. ranks nationally

Where this company's total reported payments fall within the full national distribution of all 1,925 companies in CMS Open Payments, not just its nearest peers.

Taiho Oncology, Inc.'s total vs. every reporting company

CMS Open Payments, Program Year 2024

$17,611,301 Top 5% higher than 95% of 1,925 reporting companies

$9–$28: 3 reporting companies (0%). Below this entry. $28–$87: 10 reporting companies (1%). Below this entry. $87–$270: 20 reporting companies (1%). Below this entry. $270–$838: 41 reporting companies (2%). Below this entry. $838–$2,603: 76 reporting companies (4%). Below this entry. $2,603–$8,084: 114 reporting companies (6%). Below this entry. $8,084–$25,112: 167 reporting companies (9%). Below this entry. $25,112–$78,003: 249 reporting companies (13%). Below this entry. $78,003–$242,294: 295 reporting companies (15%). Below this entry. $242,294–$752,621: 270 reporting companies (14%). Below this entry. $752,621–$2,337,813: 263 reporting companies (14%). Below this entry. $2,337,813–$7,261,783: 200 reporting companies (10%). Below this entry. $7,261,783–$22,556,757: 133 reporting companies (7%). This entry sits in this band. $22,556,757–$70,066,439: 45 reporting companies (2%). Above this entry. $70,066,439–$217,642,369: 26 reporting companies (1%). Above this entry. $217,642,369–$676,046,922: 13 reporting companies (1%). Above this entry. This company $9 $676,046,922 every reporting company, bucketed by value

Each bar is a progressively wider band; taller bars hold more reporting companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source CMS Open Payments · 2024

What the Data Shows for Taiho Oncology, Inc.

$17,611,301.25: that is what Taiho Oncology, Inc. reported in payments to 5,970 physicians and teaching hospitals during Program Year 2024, spread across 6,767 transactions ($2.6K per transaction, $2.9K per recipient). The company sits at rank #104 of 1,925, representing 0.1% of all industry payments reported nationwide for the year.

The 7-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Services Other Than Consulting" at $340.3K, accounting for 1.9% of the company's reported total and 97 transactions.

General Payment Breakdown by Type

Taiho Oncology, Inc. made 7 types of general payments. "Compensation for Services Other Than Consulting" is the largest category at $340.3K, 1.9% of the company's reported total.

How Taiho Oncology, Inc. divides its payments

General-payment categories, ordered by reported total

1. Compensation for Services…$340.3K2. Consulting Fee$213.5K3. Food and Beverage$124.3K4. Space Rental or Facility …$94.0K5. Travel and Lodging$57.4K6. Education$10.4K7. Compensation for Faculty …$4.5K
Payment Type Amount Transactions
Compensation for Services Other Than Consulting $340.3K 97
Consulting Fee $213.5K 106
Food and Beverage $124.3K 5,407
Space Rental or Facility Fees $94.0K 29
Travel and Lodging $57.4K 288
Education $10.4K 9
Compensation for Faculty or Speaker (Medical Education) $4.5K 34

Recipient Concentration in General Payments

The five largest recipient relationships account for $197,775.42 (23.4%) of $844,416.49 in this company's General Payments records across 3,227 recipients. This is a CMS Open Payments Program Year 2024 General Payments view only: it excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Taiho Oncology, Inc.

The five named recipients with the highest reported General Payments from this company

Michael Morse$91.5KBart Scott$31.7KBen George$29.5KMayo Clinic Hospital$22.6KPutao Cen$22.6K
  1. 1

    Michael Morse

    $91,456.88 across 84 reported transactions

  2. 2

    Bart Scott

    $31,667.39 across 20 reported transactions

  3. 3

    Ben George

    $29,469.83 across 19 reported transactions

  4. 4

    Mayo Clinic Hospital

    $22,595.00 across 5 reported transactions

  5. 5

    Putao Cen

    $22,586.32 across 22 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Payment Size Analysis

Average transaction size: $2.6K. Average per recipient: $2.9K.

Total Amount

$17,611,301.25

Avg per Transaction

$2.6K

Avg per Recipient

$2.9K

Payment Transparency Context

What is the Sunshine Act?

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.9B

across 1,925 companies

Taiho Oncology, Inc. Share

0.1%

#104 by total payments

Companies with Similar Payment Volumes

Pharmaceutical companies with payment totals similar to Taiho Oncology, Inc.

Becton, Dickinson and Company

$17.8M 12,620 recipients

Ultragenyx Pharmaceutical Inc.

$17.8M 2,488 recipients

CSL Plasma Inc.

$17.9M 12,905 recipients

Sarepta Therapeutics, Inc.

$17.2M 1,307 recipients

Spinecraft, LLC

$18.2M 27 recipients

Align Technology, Inc.

$17.0M 55,540 recipients

Frequently Asked Questions

How much did Taiho Oncology, Inc. pay to physicians and hospitals in 2024? ▾
Taiho Oncology, Inc. made $17,611,301.25 in payments to physicians and hospitals in Program Year 2024, across 6,767 individual transactions. This represents 0.1% of all industry payments reported to CMS Open Payments.
How many physicians received payments from Taiho Oncology, Inc.? ▾
5,970 physicians and teaching hospitals received payments from Taiho Oncology, Inc. in 2024, averaging $2.9K per recipient.
What types of payments did Taiho Oncology, Inc. make? ▾
General payments from Taiho Oncology, Inc. span 7 distinct categories, covering things like consulting, meals, and travel. The largest general-payment category was "Compensation for Services Other Than Consulting" at $340.3K, representing 1.9% of the company's reported total.
How does Taiho Oncology, Inc. rank among pharmaceutical companies? ▾
By total payment amount, Taiho Oncology, Inc. sits at #104 of 1,925 companies in the CMS Open Payments database for 2024.
What is the average payment size from Taiho Oncology, Inc.? ▾
In 2024, Taiho Oncology, Inc. averaged $2.6K per transaction across 6,767 transactions to 5,970 recipients.
Where does the payment data for Taiho Oncology, Inc. come from? ▾
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Taiho Oncology, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-25.